tert-butyl-(3S,4S)-pyrrolidine | 1260619-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl-(3S,4S)-pyrrolidine
• 英文别名: tert-Butyl-(3S)-pyrrolidin；(S)-3-(tert-Butyl)pyrrolidine；(3S)-3-tert-butylpyrrolidine
• CAS: 1260619-48-4
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: LMVHALAYUBESJG-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (E)-3,3-dimethyl-1-nitrobut-1-ene 、 (R)-(-)-(2,2-Diphenylcyclopentoxy)ethene 在 platinum(IV) oxide 氢气 、 甲基铝双(2,6-二苯基苯酚) 作用下， 生成 tert-butyl-(3S,4S)-pyrrolidine 、 tert-butyl-(3R,4R)-pyrrolidine
  参考文献：
  名称：

  Asymmetric Nitroalkene [4 + 2] Cycloadditions: Enantioselective Synthesis of 3-Substituted and 3,4-Disubstituted Pyrrolidines

  摘要：

  2-Substituted 1-nitroalkenes undergo highly diastereoselective, Lewis-acid-promoted, [4 + 2] cycloaddition with chiral vinyl ethers derived from (R)-2,2-diphenylcyclopentanol and (1R,2S)-2-phenylcyclohexanol to afford cyclic nitronates in high yields. The resulting nitronates were reduced with hydrogen at 160 psi in the presence of platinum oxide to afford enantiomerically enriched pyrrolidines (both as the free base and N-protected derivatives) in good yields. A series of 3-substituted pyrrolidines (71-97% ee) were prepared, as well as (3S,4R)-4-methyl-3-phenyl-N-(p-tolylsulfonyl)pyrrolidine (92% ee) and (3S,4S)-3,4-diphenylpyrrolidine (99% ee). The chiral auxiliaries can be recovered in nearly quantitative yields after hydrogenation.

  DOI：

  10.1021/jo00115a043

文献信息

• HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170320860A1

  公开（公告）日：2017-11-09

  Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一个的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构： 其中变量的定义在此提供。
• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20150336962A1

  公开（公告）日：2015-11-26

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

  这里描述了化合物的公式（00A）及其作为Janus激酶抑制剂的使用方法。
• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• TRIAZOLYL PHENYL BENZENESULFONAMIDES
  申请人：Charvat T. Trevor

  公开号：US20080039465A1

  公开（公告）日：2008-02-14

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

  提供了一些化合物，它们作为CCR2或CCR9受体的有效拮抗剂。动物测试表明这些化合物对于治疗CCR2和CCR9的典型疾病炎症非常有用。这些化合物通常是芳基磺酰胺衍生物，并且在制药组合物、治疗CCR2介导的疾病、CCR9介导的疾病的方法、作为CCR2拮抗剂识别的测定的控制剂以及作为CCR9拮抗剂识别的测定的控制剂中非常有用。
• Diphenyl Substituted Alkanes as Flap Inhibitors
  申请人：Chu Lin

  公开号：US20070287736A1

  公开（公告）日：2007-12-13

  The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

  本发明提供了I式化合物，它们是5-脂氧合酶激活蛋白抑制剂。I式化合物可用作抗动脉粥样硬化、抗哮喘、抗过敏、抗炎和细胞保护剂。